## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.89 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: declining volume (56% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($61.13)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 10)

**1. HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: PR Newswire | 20251205T193035 | Bearish | Relevance: 100%
- Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of DexCom to contact them to discuss potential rights, including seeking corporate governance reforms or the return of funds to the company. Shareholder involvement is highlighted as a way to improve company policies and enhance shareholder value.

**2. Lowey Dannenberg Notifies DexCom, Inc. (“DexCom” or the**
- Source: GlobeNewswire | 20251205T175343 | Bearish | Relevance: 100%
- Lowey Dannenberg P.C. has filed a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) alleging violations of federal securities laws. The lawsuit claims that DexCom made unauthorized material design changes to its G6 and G7 devices, rendering them less reliable and posing health risks, which led to a precipitous decline in DexCom's stock value. Investors who suffered losses exceeding $100,000 are encouraged to contact the firm.

**3. DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – DXCM**
- Source: FOX 2 | 20251205T140837 | Bearish | Relevance: 100%
- The DJS Law Group has announced a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged securities law violations. The lawsuit claims DexCom made false and misleading statements, specifically regarding unauthorized product changes that lowered reliability and created health risks. Shareholders who purchased DXCM shares between July 26, 2024, and September 17, 2025, are encouraged to contact the firm to discuss their rights.

**4. DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – DXCM**
- Source: www.yourerie.com | 20251205T140754 | Bearish | Relevance: 100%
- The DJS Law Group has announced a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged securities law violations. The lawsuit claims DexCom made false and misleading statements and implemented product changes without FDA authorization, leading to reliability issues and health risks for users. Shareholders who purchased DXCM shares between July 26, 2024, and September 17, 2025, are encouraged to contact the firm to discuss their rights.

**5. Pomerantz LLP Pursues Class Action Against DexCom, Inc. – DXCM**
- Source: CIProud.com | 20251205T120824 | Bearish | Relevance: 100%
- Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and certain officers, alleging materially false and misleading statements regarding the company's continuous glucose monitoring systems. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 devices, rendering them less reliable and posing health risks, which led to significant stock price drops following an FDA warning letter, an Oppenheimer downgrade, and a Hunterbrook report exposing severe issues. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, have until December 26, 2025, to seek appointment as Lead Plaintiff.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |
| 2025-11-10 | Morgan Stanley | $63 | $89 | -29% |
| 2025-11-07 | Argus Research | $90 | $100 | -10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |
| 2025-11-10 | Morgan Stanley | main | Equal-Weight |
| 2025-11-07 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)
- JPMORGAN CHASE & CO: 3.2% (+101.9%)

### Key Risks

1. Long-term trend broken: trading 12.7% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.89 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.89 |
| Forward P/E | 26.4 |
| Current P/E | 31.7 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 5.3% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 at 0.6% confirms short-term momentum alignment. AM_20 at 7.7% shows strong absolute momentum above own 20MA. Outperforming sector by 7.6pp, stock-specific strength. Below SMA200 (0.87x), long-term trend not supportive. MACD histogram positive (0.94), confirming momentum. RSI neutral at 59. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.30% (CS: 86) | Strong |
| RSI_14 | 59.3 | Neutral |
| MACD Histogram | 0.94 | Bullish |
| vs SMA20 | 1.077x | Above |
| vs SMA50 | 1.022x | Above |
| vs SMA200 | 0.873x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $65.49
- **Stop Loss:** $61.13 (6.7% risk)
- **Target:** $74.21 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 114
- **Position Value:** $7,465.86
- **Portfolio %:** 7.47%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*